Switch theme
Sign up to access all valuation multiples
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
1999
704
LTM Revenue $321M
LTM EBITDA -$178M
-$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Galapagos has a last 12-month revenue (LTM) of $321M and a last 12-month EBITDA of -$178M.
In the most recent fiscal year, Galapagos achieved revenue of $310M and an EBITDA of $48.7M.
Galapagos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Galapagos valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $321M | XXX | $310M | XXX | XXX | XXX |
| Gross Profit | $296M | XXX | $270M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | -$178M | XXX | $48.7M | XXX | XXX | XXX |
| EBITDA Margin | -55% | XXX | 16% | XXX | XXX | XXX |
| EBIT | -$210M | XXX | -$212M | XXX | XXX | XXX |
| EBIT Margin | -65% | XXX | -68% | XXX | XXX | XXX |
| Net Profit | -$18.2M | XXX | $83.2M | XXX | XXX | XXX |
| Net Margin | -6% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Galapagos's stock price is EUR 26 (or $29).
Galapagos has current market cap of EUR 1.7B (or $1.9B), and EV of -EUR 1.6B (or -$1.8B).
See Galapagos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.8B | $1.9B | XXX | XXX | XXX | XXX | $-0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Galapagos has market cap of $1.9B and EV of -$1.8B.
Galapagos's trades at -5.8x EV/Revenue multiple, and -36.8x EV/EBITDA.
Equity research analysts estimate Galapagos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Galapagos has a P/E ratio of -104.6x.
See valuation multiples for Galapagos and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | -$1.8B | XXX | -$1.8B | XXX | XXX | XXX |
| EV/Revenue | -5.6x | XXX | -5.8x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | -36.8x | XXX | XXX | XXX |
| EV/EBIT | 8.5x | XXX | 8.5x | XXX | XXX | XXX |
| EV/Gross Profit | -6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -104.6x | XXX | 22.8x | XXX | XXX | XXX |
| EV/FCF | 3.6x | XXX | 4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGalapagos's last 12 month revenue growth is -12%
Galapagos's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.7M for the same period.
Galapagos's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Galapagos's rule of X is -85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Galapagos and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -12% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -55% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 10% | XXX | 4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -85% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 122% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 156% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galapagos acquired XXX companies to date.
Last acquisition by Galapagos was XXXXXXXX, XXXXX XXXXX XXXXXX . Galapagos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Galapagos founded? | Galapagos was founded in 1999. |
| Where is Galapagos headquartered? | Galapagos is headquartered in Netherlands. |
| How many employees does Galapagos have? | As of today, Galapagos has 704 employees. |
| Who is the CEO of Galapagos? | Galapagos's CEO is Dr. Paulus Stoffels. |
| Is Galapagos publicy listed? | Yes, Galapagos is a public company listed on AMS. |
| What is the stock symbol of Galapagos? | Galapagos trades under GLPG ticker. |
| When did Galapagos go public? | Galapagos went public in 2005. |
| Who are competitors of Galapagos? | Similar companies to Galapagos include e.g. Julphar, Benevolent AI, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Galapagos? | Galapagos's current market cap is $1.9B |
| What is the current revenue of Galapagos? | Galapagos's last 12 months revenue is $321M. |
| What is the current revenue growth of Galapagos? | Galapagos revenue growth (NTM/LTM) is -12%. |
| What is the current EV/Revenue multiple of Galapagos? | Current revenue multiple of Galapagos is -5.6x. |
| Is Galapagos profitable? | Yes, Galapagos is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Galapagos? | Galapagos's last 12 months EBITDA is -$178M. |
| What is Galapagos's EBITDA margin? | Galapagos's last 12 months EBITDA margin is -55%. |
| What is the current EV/EBITDA multiple of Galapagos? | Current EBITDA multiple of Galapagos is 10.1x. |
| What is the current FCF of Galapagos? | Galapagos's last 12 months FCF is -$499M. |
| What is Galapagos's FCF margin? | Galapagos's last 12 months FCF margin is -156%. |
| What is the current EV/FCF multiple of Galapagos? | Current FCF multiple of Galapagos is 3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
